This technology is a method of using metabolic profiling-related biomarkers to identify newborns or infants with autism spectrum disorder for early intervention.
Autism spectrum disorder (ASD) is increasingly common in the United States, affecting children of various racial, ethnic, and socioeconomic groups. Current interventions for ASD largely use applied behavior analysis (ABA). However, this can be costly, restrictive, and involves a later mean age for diagnosis. Improving methods that can provide earlier intervention for ASD would have a great impact on proper, timely, and individualized intervention, outcomes, and pathogenesis.
This technology describes biomarkers that can be found in plasma for early identification of children at risk for autism spectrum disorder (ASD). Specifically, this involves using metabolomic analyses for profiling and identification of dysregulated pathways. Consequently, this technology can be used to determine early biomarkers for early diagnosis and intervention of ASD to improve outcomes. The metabolomic profiles that may be used and associated with ASD could potentially enable intervention as early as birth.
Patent Pending
IR CU23349
Licensing Contact: Kristin Neuman